Loading organizations...
Boston-based Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel synthetic peptide treatments for orphan pulmonary and fibrosis indications. Following its October 2023 acquisition of Lung Therapeutics, the publicly traded enterprise shifted its primary clinical focus from oncology to respiratory diseases, advancing its lead product candidate, LTI-03, for idiopathic pulmonary fibrosis. The micro-cap company historically raised over $100 million in private and public funding, including a $56 million initial public offering on the NASDAQ exchange in June 2017 when it operated with 14 employees. To support its restructured clinical pipeline, the firm secured a $4.7 million private placement in January 2024, building upon historical backing from notable venture investors like Novartis Venture Fund and Apple Tree Partners. Aileron Therapeutics was founded in 2005 by Gregory Verdine, Rosana Kapeller, and Joseph A. Yanchik III.
Aileron Therapeutics has raised $133.0M across 6 funding rounds.
Aileron Therapeutics has raised $133.0M in total across 6 funding rounds.
Aileron Therapeutics has raised $133.0M across 6 funding rounds. Most recently, it raised $33.0M Series E in October 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2014 | $33M Series E | AJU IB Investment | Abingworth, ATP (apple Tree Partners), Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis, Roche, SR ONE | Announced |
| Nov 1, 2013 | $30M Series E | — | Abingworth, ATP (apple Tree Partners), Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis, Roche, SR ONE | Announced |
| Jan 1, 2013 | $12M Series D | — | Abingworth, ATP (apple Tree Partners) | Announced |
| Jun 1, 2009 | $40M Series D | — | Abingworth, ATP (apple Tree Partners) | Announced |
| Apr 1, 2008 | $11M Series C | — | ATP (apple Tree Partners) | Announced |
| Jun 1, 2007 | $7M Series B | Apple Tree Partners, Novartis | ATP (apple Tree Partners) | Announced |
Aileron Therapeutics has raised $133.0M in total across 6 funding rounds.
Aileron Therapeutics's investors include AJU IB Investment, Abingworth, ATP (Apple Tree Partners), Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis, Roche, SR One.
# Aileron Therapeutics: Correcting the Record
Aileron Therapeutics is not a technology company—it is a clinical-stage biopharmaceutical company. This is an important distinction that affects how we should evaluate the organization.
Aileron Therapeutics (NASDAQ: ALRN) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing novel therapeutics for diseases with significant unmet medical needs.[1][2] Rather than building software or technology platforms, the company develops pharmaceutical drug candidates through rigorous clinical trials and regulatory processes.
The company's primary focus is advancing LTI-01, a proenzyme therapeutic candidate designed to treat loculated pleural effusions (LPE)—a serious complication that can follow pneumonia, heart failure, and other illnesses.[1] LTI-01 is designed for intrapleural administration and offers a potential non-surgical treatment option for patients who currently have limited alternatives. The company serves patients with specific medical conditions and operates within the highly regulated pharmaceutical development ecosystem rather than the technology sector.
Aileron Therapeutics began with a focus on stapled peptides, a novel class of drugs representing the company's original technological foundation.[1] However, the company underwent a significant strategic shift in late 2023/early 2024, narrowing its focus considerably. This pivot involved acquiring LTI-01 through a merger, which became the centerpiece of the company's current pipeline and represents a deliberate repositioning toward a more focused clinical development strategy.[1]
Aileron operates within the clinical-stage biopharmaceutical sector, where companies develop novel therapies to address unmet medical needs. The company's focus on rare or underserved conditions like loculated pleural effusions reflects a broader trend in biotech toward precision medicine and targeted therapeutics. Post-merger financing has extended the company's operational runway, positioning it to advance LTI-01 through critical development phases.[1]
Aileron's trajectory depends on successful clinical advancement of LTI-01. The company's ability to demonstrate safety and efficacy in trials, navigate regulatory approval, and ultimately bring a non-surgical treatment option to market will determine its long-term viability. As a clinical-stage company, Aileron remains in the capital-intensive phase of drug development, where execution on clinical milestones and regulatory progress are the primary measures of success.
